Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,110
  • Shares Outstanding, K 159,095
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,540 K
  • 60-Month Beta 1.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.49
Trade CTXR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.26
  • Most Recent Earnings $-0.06 on 02/14/24
  • Latest Earnings Date 05/10/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 405.09% ( +30.80%)
  • Historical Volatility 65.34%
  • IV Percentile 57%
  • IV Rank 29.78%
  • IV High 1,290.45% on 10/10/23
  • IV Low 29.63% on 05/17/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 134
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 4,980
  • Open Int (30-Day) 4,596

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6500 +38.65%
on 03/12/24
0.9303 -3.13%
on 03/28/24
+0.1154 (+14.69%)
since 02/28/24
3-Month
0.6000 +50.20%
on 02/08/24
0.9303 -3.13%
on 03/28/24
+0.1295 (+16.78%)
since 12/28/23
52-Week
0.6000 +50.20%
on 02/08/24
1.7100 -47.30%
on 04/17/23
-0.1288 (-12.50%)
since 03/28/23

Most Recent Stories

More News
Goodbye ’23

Monday U.S. and Canada Christmas Day, Markets Closed Tuesday U.S. Economic ...

CVM : 1.8900 (unch)
CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...

CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir, who passed away...

CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIRâ„¢

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has received additional guidance...

CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...

CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...

CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...

CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIRâ„¢ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the U.S. Food and Drug Administration (FDA) has...

CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

CTXR : 0.8994 (+9.14%)
Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR) today announced results from the Company's Phase 2b clinical study of...

CTXR : 0.8994 (+9.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.8927
2nd Resistance Point 0.8614
1st Resistance Point 0.8427
Last Price 0.8994
1st Support Level 0.7927
2nd Support Level 0.7614
3rd Support Level 0.7427

See More

52-Week High 1.7100
Fibonacci 61.8% 1.2860
Fibonacci 50% 1.1550
Fibonacci 38.2% 1.0240
Last Price 0.8994
52-Week Low 0.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar